| Name | Title | Contact Details |
|---|
Russell Reynolds Associates (RRA) is a global leadership advisory and executive search firm founded in 1969 in New York City. Initially focused on financial services, RRA has expanded its expertise to various industries, including healthcare, consumer goods, technology, and industrial sectors. With 47 offices worldwide, the firm specializes in identifying and developing transformational leaders for public, private, and non-profit organizations. RRA offers a range of services, including executive search for C-suite and board roles, leadership advisory for succession planning and team effectiveness, and board advisory for governance and director recruitment. The firm utilizes proprietary assessment tools, such as the Leadership Span Assessment, to evaluate leadership capabilities. RRA serves a diverse clientele, including Fortune 500 companies and non-profits, and emphasizes a high-touch approach to address challenges like sustainability and digital transformation. With over 470 consultants across 26+ countries, RRA maintains a strong international presence and adapts to evolving leadership demands.
Tower Street Insurance was established to provide the most effective solutions to manage your commercial and personal risks. It is our privilege to represent and partner with each of our clients. We have built our reputation on offering successful families and businesses the highest level of service rooted in transparency and trust. With our extensive resources and exclusive carrier options, we are able to create protection strategies that provide custom solutions with the broadest coverage, superior claims service, and overall best value. However, we also understand that choosing a risk management solution involves more than simply obtaining coverage, so we go beyond offering policies backed by the best insurance companies in the business. We listen to specific needs, form solid relationships, and take the time to walk each client through all aspects of their personalized insurance plan. After the plan is in place, we continue to serve as an on-call partner devoted to our clients risk management success year-round. At Tower Street Insurance, our entire team is passionate about providing a consistently exceptional experience. Our commitment to perfection, attention to detail, and many years in the industry allow us to confidently provide a solution for all risk management and insurance needs. We hope we will have the opportunity to provide a comprehensive insurance solution for your business and family.
Hyundai Motor Group Metaplant America (HMGMA) is an advanced automotive manufacturing facility located in Ellabell, Georgia. It serves as Hyundais third production hub in the U.S., complementing existing facilities in Alabama and Georgia. Designed as a Software Defined Factory, HMGMA integrates AI and robotics to support Hyundais vision for a technology-driven future in mobility. The facility spans 2,900 acres and will employ over 8,500 workers, with an additional 6,900 jobs created at off-site suppliers. HMGMA aims to produce 500,000 vehicles annually, including electric and hybrid models like the Hyundai IONIQ 5 and IONIQ 9. The plant represents a significant investment of approximately $12.6 billion, marking one of the largest economic development projects in Georgias history. HMGMA also emphasizes sustainability by utilizing hydrogen fuel-cell electric trucks for logistics, showcasing its commitment to environmentally responsible operations. The facility is expected to have a substantial economic impact, creating nearly 40,000 jobs in Georgia and supporting over 570,000 jobs nationwide.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.